@article{SalkerSinghZengetal.2017,
  author    = {Salker, Madhuri S. and Singh, Yogesh and Zeng, Ni and Chen, Hong and Zhang, Shaqiu and Umbach, Anja T. and Fakhri, Hajar and Kohlhofer, Ursula and Quintanilla-Martinez, Leticia and Durairaj, Ruban R. Peter and Barros, Flavio S. V. and Vrljicak, Pavle and Ott, Sascha and Brucker, Sara Y. and Wallwiener, Diethelm and Madunić, Ivana Vrhovac and Breljak, Davorka and Sabolić, Ivan and Koepsell, Hermann and Brosens, Jan J. and Lang, Florian},
  title     = {Loss of endometrial sodium glucose cotransporter SGLT1 is detrimental to embryo survival and fetal growth in pregnancy},
  series = {Scientific Reports},
  volume    = {7},
  journal   = {Scientific Reports},
  doi       = {10.1038/s41598-017-11674-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173814},
  year      = {2017},
  abstract  = {Embryo implantation requires a hospitable uterine environment. A key metabolic change that occurs during the peri-implantation period, and throughout early pregnancy, is the rise in endometrial glycogen content. Glycogen accumulation requires prior cellular uptake of glucose. Here we show that both human and murine endometrial epithelial cells express the high affinity Na\(^+\)-coupled glucose carrier SGLT1. Ussing chamber experiments revealed electrogenic glucose transport across the endometrium in wild type (\(Slc5a1^{+/+}\)) but not in SGLT1 defcient (\(Slc5a1^{-/-}\)) mice. Endometrial glycogen content, litter size and weight of offspring at birth were signifcantly lower in \(Slc5a1^{-/-}\) mice. In humans, \(SLC5A1\) expression was upregulated upon decidualization of primary endometrial stromal cells. Endometrial \(SLC5A1\) expression during the implantation window was attenuated in patients with recurrent pregnancy loss when compared with control subjects. Our fndings reveal a novel mechanism establishing adequate endometrial glycogen stores for pregnancy. Disruption of this histiotrophic pathway leads to adverse pregnancy outcome.},
  language  = {en}
}
@article{OttoFriedrichMadunićetal.2020,
  author    = {Otto, Christoph and Friedrich, Alexandra and Madunić, Ivana Vrhovac and Baumeier, Christian and Schwenk, Robert W. and Karaica, Dean and Germer, Christoph-Thomas and Sch{\"u}rmann, Annette and Sabolić, Ivan and Koepsell, Hermann, Hermann},
  title     = {Antidiabetic Effects of a Tripeptide That Decreases Abundance of Na\(^+\)-D-glucose Cotransporter SGLT1 in the Brush-Border Membrane of the Small Intestine},
  series = {ACS Omega},
  volume    = {5},
  journal   = {ACS Omega},
  number    = {45},
  doi       = {10.1021/acsomega.0c03844},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-230654},
  pages     = {29127-29139},
  year      = {2020},
  abstract  = {In enterocytes, protein RS1 (RSC1A1) mediates an increase of glucose absorption after ingestion of glucose-rich food via upregulation of Na+-D-glucose cotransporter SGLT1 in the brush-border membrane (BBM). Whereas RS1 decelerates the exocytotic pathway of vesicles containing SGLT1 at low glucose levels between meals, RS1-mediated deceleration is relieved after ingestion of glucose-rich food. Regulation of SGLT1 is mediated by RS1 domain RS1-Reg, in which Gln-Ser-Pro (QSP) is effective. In contrast to QSP and RS1-Reg, Gln-Glu-Pro (QEP) and RS1-Reg with a serine to glutamate exchange in the QSP motif downregulate the abundance of SGLT1 in the BBM at high intracellular glucose concentrations by about 50\%. We investigated whether oral application of QEP improves diabetes in db/db mice and affects the induction of diabetes in New Zealand obese (NZO) mice under glucolipotoxic conditions. After 6-day administration of drinking water containing 5 mM QEP to db/db mice, fasting glucose was decreased, increase of blood glucose in the oral glucose tolerance test was blunted, and insulin sensitivity was increased. When QEP was added for several days to a high fat/high carbohydrate diet that induced diabetes in NZO mice, the increase of random plasma glucose was prevented, accompanied by lower plasma insulin levels. QEP is considered a lead compound for development of new antidiabetic drugs with more rapid cellular uptake. In contrast to SGLT1 inhibitors, QEP-based drugs may be applied in combination with insulin for the treatment of type 1 and type 2 diabetes, decreasing the required insulin amount, and thereby may reduce the risk of hypoglycemia.},
  language  = {en}
}